Abstract
Microscopic haematuria is the presenting symptom of several conditions, either heritable or acquired. A well-recognized familial condition is Alport syndrome, either of X-linked or autosomal recessive inheritance, as well as thin basement membrane nephropathy (TBMN) because of heterozygous collagen IV mutations. Even though microscopic haematuria of TBMN was long considered as a benign disease with excellent prognosis, more recent data suggest that development of chronic kidney disease (CKD) and even end-stage kidney disease (ESKD) is not a rare finding, perhaps owing to the cofounding role of modifier genes and other factors. Recent investigations in London and Cyprus culminated in the identification of another autosomal dominant condition that presents with microscopic haematuria because of heterozygous mutations in the CFHR5 gene, which apparently plays a pivotal role in the regulation of the alterative pathway of complement system, which constitutes a significant part of innate immunity in humans. Histologically, the hallmark observation is the isolated glomerular deposition of C3 complement in the absence of immune complexes. It is considered one of the C3 glomerulopathies, and it may or may not be accompanied by mild membranoproliferative glomerulonephritis. Interestingly, a single mutation has been identified so far, a duplication of exons 2–3 of the CFHR5 gene, and it has been described in patients of Greek-Cypriot descend only, perhaps originating on the Troodos mountains of Cyprus. Thus far, no patient with a mutation in this gene has been diagnosed in any other population. In Cyprus, it has been found in clusters of families in neighbouring villages in a total of 136 patients, and it constitutes a strong founder phenomenon. About 50% of patients over 50 years have progressed to CKD, and 14% of all patients progressed to ESKD. It is not quite well understood why males run a much higher risk to progress to CKD, compared to women.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Athanasiou Y, Voskarides K, Gale D, Damianou L, Patsias C, Zavros M et al (2011) Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees. Clin J Am Soc Nephrol 6:1436–1446
Deltas C (2004) Inherited diseases and Cyprus reality. A historico-genetic approach. In: The 30th annals of the Cyprus Research Center (Epetirida), Ministry of Education and Culture, Nicosia, Cyprus (Greek), pp 457–489
Deltas C, Pierides A, Voskarides K (2012) The role of molecular genetics in diagnosing familial hematuria(s). Pediatr Nephrol, DOI: 10.1007/s00467-011-1935-5
Gale DP, de Jorge EG, Cook HT, Martinez-Barricarte R, Hadjisavvas A, Adam G et al (2010) Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 376:794–801
Grekas D, Morley AR, Wilkinson R, Kerr DN (1984) Isolated C3 deposition in patients without systemic disease. Clin Nephrol 21:270–274
Murphy B, Georgiou T, Machet D, Hill P, McRae J (2002) Factor H-related protein-5: a novel component of human glomerular immune deposits. Am J Kidney Dis 39:24–27
Kashtan CE (2005) Familial hematurias: what we know and what we don’t. Pediatr Nephrol 20:1027–1035
Papagregoriou G, Erguler K, Dweep H, Voskarides K, Koupepidou P, Athanasiou A et al (2012) A miR-1207-5p binding site polymorphism abolishes regulation of HBEGF and is associated with disease severity in CFHR5 nephropathy. PLoS ONE 7(2):e31021 [Epub 2012 Feb 2]
Pierides A, Voskarides K, Athanasiou Y, Ioannou K, Damianou L, Arsali M et al (2009) Clinico-pathological correlations in 127 patients in 11 large pedigrees, segregating one of three heterozygous mutations in the COL4A3/COL4A4 genes associated with familial haematuria and significant late progression to proteinuria and chronic kidney disease from focal segmental glomerulosclerosis. Nephrol Dial Transplant 24:2721–2729
Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30:e57
Servais A, Frémeaux-Bacchi V, Lequintrec M, Salomon R, Blouin J, Knebelmann B et al (2007) Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 44:193–199
Voskarides K, Damianou L, Neocleous V, Zouvani I, Christodoulidou S, Hadjiconstantinou V et al (2007) COL4A3/COL4A4 mutations producing focal segmental glomerulosclerosis and renal failure in thin basement membrane nephropathy. J Am Soc Nephrol 18:3004–3016
Voskarides Κ, Patsias C, Pierides A, Deltas C (2008) COL4A3 Founder mutations in Greek-Cypriot families with thin basement membrane nephropathy and focal segmental glomerulosclerosis dating from around 18th century. Genet Test 12(2):273–278
Voskarides K, Arsali M, Athanasiou Y, Elia A, Pierides A, Deltas C (2012) Evidence that NPHS2-R229Q predisposes to proteinuria and renal failure in familial hematuria. Pediatr Nephrol, DOI: 10.1007/s00467-011-2084-6
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Deltas, C., Gale, D., Cook, T., Voskarides, K., Athanasiou, Y., Pierides, A. (2013). C3 Glomerulonephritis/CFHR5 Nephropathy Is an Endemic Disease in Cyprus: Clinical and Molecular Findings in 21 Families. In: Lambris, J., Holers, V., Ricklin, D. (eds) Complement Therapeutics. Advances in Experimental Medicine and Biology, vol 735. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-4118-2_12
Download citation
DOI: https://doi.org/10.1007/978-1-4614-4118-2_12
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-4117-5
Online ISBN: 978-1-4614-4118-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)